Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Current imaging options do not assess prostate cancer well. This study will combine two
magnetic resonance imaging modalities, MRI and MRSI, in order to determine the utility to
physicians and patients with prostate cancer in making treatment decisions and seeing how
well various types of treatment work. Hyperpolarized pyruvate (13C) is an investigational
product that may enhance the imaging capability of MRI and MRSI. Hyperpolarized pyruvate will
be injected into the body to determine how it is metabolized and how it's metabolism can be
assessed using MR imaging.
The purpose of this study is to determine the safety and metabolism of hyperpolarized
pyruvate in humans, and how this can be used to increase the effectiveness of MR imaging with
regards to patient care.